First Dose of the BNT162b2 mRNA COVID-19 Vaccine Reduces Symptom Duration and Viral Clearance in Healthcare Workers
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected more than one hundred million people since the beginning of the worldwide pandemic. In this study, data from a large hospital in central Italy was used to evaluate the impact of the first dose of the BNT162b2 mRNA vaccine on S...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-06-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/9/6/659 |
| _version_ | 1797529839049113600 |
|---|---|
| author | Luca Coppeta Ottavia Balbi Zaira Grattagliano Grazia Genga Mina Antonio Pietroiusti Andrea Magrini Matteo Bolcato Marco Trabucco Aurilio |
| author_facet | Luca Coppeta Ottavia Balbi Zaira Grattagliano Grazia Genga Mina Antonio Pietroiusti Andrea Magrini Matteo Bolcato Marco Trabucco Aurilio |
| author_sort | Luca Coppeta |
| collection | DOAJ |
| description | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected more than one hundred million people since the beginning of the worldwide pandemic. In this study, data from a large hospital in central Italy was used to evaluate the impact of the first dose of the BNT162b2 mRNA vaccine on SARS-CoV-2 infections in terms of the prevalence of symptomatic cases, symptom duration, and viral clearance timing. All vaccinated Healthcare Workers (HCWs) with positive RT-PCR by nasopharyngeal (NP) swabs were divided into two cohorts (positive RT-PCR within day 12 and positive RT-PCR between day 13 and day 21 after first dose administration) and compared for the presence and duration of symptoms and the timing of viral clearance. The same variables were evaluated across HCWs with positive RT-PCR within 6 days after first dose administration and non-vaccinated HCWs with positive RT-PCR between 1 October 2020 and 28 February 2021. Eighteen HCWs tested positive on RT-PCR by NP swab from day 1 to day 12 after the 1st dose administration (incidence rate 6.2 × 10<sup>−4</sup>) and 5 HCWs from day 13 to day 21 (incidence rate 2.3 × 10<sup>−4</sup>). Symptom duration and viral clearance timing are significantly shorter in the cohort of HCWs with positive RT-PCR 12 days after the first dose of the BNT162b2 mRNA vaccine. The administration of the first dose proved effective in reducing presence, symptom duration, and viral clearance even in HCWs vaccinated for less than 6 days. These results could have implications on public health and post-exposure prophylaxis. |
| first_indexed | 2024-03-10T10:20:29Z |
| format | Article |
| id | doaj.art-6f0e4593b8c147a38d40e83abf134525 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T10:20:29Z |
| publishDate | 2021-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-6f0e4593b8c147a38d40e83abf1345252023-11-22T00:28:12ZengMDPI AGVaccines2076-393X2021-06-019665910.3390/vaccines9060659First Dose of the BNT162b2 mRNA COVID-19 Vaccine Reduces Symptom Duration and Viral Clearance in Healthcare WorkersLuca Coppeta0Ottavia Balbi1Zaira Grattagliano2Grazia Genga Mina3Antonio Pietroiusti4Andrea Magrini5Matteo Bolcato6Marco Trabucco Aurilio7Department of Occupational Medicine, University of Rome Tor Vergata, 00188 Roma, ItalyDepartment of Occupational Medicine, University of Rome Tor Vergata, 00188 Roma, ItalyDepartment of Occupational Medicine, University of Rome Tor Vergata, 00188 Roma, ItalyDepartment of Occupational Medicine, University of Rome Tor Vergata, 00188 Roma, ItalyDepartment of Occupational Medicine, University of Rome Tor Vergata, 00188 Roma, ItalyDepartment of Occupational Medicine, University of Rome Tor Vergata, 00188 Roma, ItalyLegal Medicine, University of Padua, 35121 Padova, ItalyDepartment of Medicine and Health Sciences “Vincenzo Tiberio”, University of Molise, 86100 Campobasso, ItalySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected more than one hundred million people since the beginning of the worldwide pandemic. In this study, data from a large hospital in central Italy was used to evaluate the impact of the first dose of the BNT162b2 mRNA vaccine on SARS-CoV-2 infections in terms of the prevalence of symptomatic cases, symptom duration, and viral clearance timing. All vaccinated Healthcare Workers (HCWs) with positive RT-PCR by nasopharyngeal (NP) swabs were divided into two cohorts (positive RT-PCR within day 12 and positive RT-PCR between day 13 and day 21 after first dose administration) and compared for the presence and duration of symptoms and the timing of viral clearance. The same variables were evaluated across HCWs with positive RT-PCR within 6 days after first dose administration and non-vaccinated HCWs with positive RT-PCR between 1 October 2020 and 28 February 2021. Eighteen HCWs tested positive on RT-PCR by NP swab from day 1 to day 12 after the 1st dose administration (incidence rate 6.2 × 10<sup>−4</sup>) and 5 HCWs from day 13 to day 21 (incidence rate 2.3 × 10<sup>−4</sup>). Symptom duration and viral clearance timing are significantly shorter in the cohort of HCWs with positive RT-PCR 12 days after the first dose of the BNT162b2 mRNA vaccine. The administration of the first dose proved effective in reducing presence, symptom duration, and viral clearance even in HCWs vaccinated for less than 6 days. These results could have implications on public health and post-exposure prophylaxis.https://www.mdpi.com/2076-393X/9/6/659SARS-CoV-2healthcare workersCOVID-19vaccinemRNA vaccinefirst dose administration |
| spellingShingle | Luca Coppeta Ottavia Balbi Zaira Grattagliano Grazia Genga Mina Antonio Pietroiusti Andrea Magrini Matteo Bolcato Marco Trabucco Aurilio First Dose of the BNT162b2 mRNA COVID-19 Vaccine Reduces Symptom Duration and Viral Clearance in Healthcare Workers Vaccines SARS-CoV-2 healthcare workers COVID-19 vaccine mRNA vaccine first dose administration |
| title | First Dose of the BNT162b2 mRNA COVID-19 Vaccine Reduces Symptom Duration and Viral Clearance in Healthcare Workers |
| title_full | First Dose of the BNT162b2 mRNA COVID-19 Vaccine Reduces Symptom Duration and Viral Clearance in Healthcare Workers |
| title_fullStr | First Dose of the BNT162b2 mRNA COVID-19 Vaccine Reduces Symptom Duration and Viral Clearance in Healthcare Workers |
| title_full_unstemmed | First Dose of the BNT162b2 mRNA COVID-19 Vaccine Reduces Symptom Duration and Viral Clearance in Healthcare Workers |
| title_short | First Dose of the BNT162b2 mRNA COVID-19 Vaccine Reduces Symptom Duration and Viral Clearance in Healthcare Workers |
| title_sort | first dose of the bnt162b2 mrna covid 19 vaccine reduces symptom duration and viral clearance in healthcare workers |
| topic | SARS-CoV-2 healthcare workers COVID-19 vaccine mRNA vaccine first dose administration |
| url | https://www.mdpi.com/2076-393X/9/6/659 |
| work_keys_str_mv | AT lucacoppeta firstdoseofthebnt162b2mrnacovid19vaccinereducessymptomdurationandviralclearanceinhealthcareworkers AT ottaviabalbi firstdoseofthebnt162b2mrnacovid19vaccinereducessymptomdurationandviralclearanceinhealthcareworkers AT zairagrattagliano firstdoseofthebnt162b2mrnacovid19vaccinereducessymptomdurationandviralclearanceinhealthcareworkers AT graziagengamina firstdoseofthebnt162b2mrnacovid19vaccinereducessymptomdurationandviralclearanceinhealthcareworkers AT antoniopietroiusti firstdoseofthebnt162b2mrnacovid19vaccinereducessymptomdurationandviralclearanceinhealthcareworkers AT andreamagrini firstdoseofthebnt162b2mrnacovid19vaccinereducessymptomdurationandviralclearanceinhealthcareworkers AT matteobolcato firstdoseofthebnt162b2mrnacovid19vaccinereducessymptomdurationandviralclearanceinhealthcareworkers AT marcotrabuccoaurilio firstdoseofthebnt162b2mrnacovid19vaccinereducessymptomdurationandviralclearanceinhealthcareworkers |